Androgenetic alopecia
Conditions
Interventions
Higher cell concentration
Intermediate cell concentration
Lower cell concentration
Placebo
Sponsors
Tokyo Medical University Hospital
Department of Dermatology, Toho University Ohashi Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients must meet all the following inclusion criteria to enroll into the study: 1. Male or female of 20 year old or more with in good health having androgenetic alopecia involving the vertex area of the scalp. 2. Males patients with androgenetic alopecia characterized as type III vertex type to type VI on the Norwood Scale. Female patients with androgenetic alopecia characterized as vertex pattern type 3 to type 6 of the Shiseido Scale. 3. Person with willingness to provide written informed consent for participation in the study, to attend all study visits and to complete all procedures required by this protocol. 4. The test areas (areas to be injected) are of uniform skin color without erythema, dark pigmentation and scars that may confound study results. 5. Person with willingness to forego the use cosmetic or medical products for hair loss throughout the course of the study.
Exclusion criteria
Exclusion criteria: The presence of any of the following will exclude a subject from study enrolment: 1. Use of any product (medication or otherwise) which interferes with the hair growth cycle. 2. Any systemic medical treatment for hair loss within the last 3 months. 3. Start of contraception treatments of oral contraceptives within the last 3 months. 4. Women who are pregnant or nursing and wish to get pregnant in clinical study period. 5. Presence of any medical condition that influences the hair growth cycle. 6. Infection has been confirmed by virological examination and syphilis testing carried out at the time of the screening. 7. Subjects diagnosed with cancer with or without chemotherapy treatment. 8. Sudden hair loss within the last 3 months unrelated to normal seasonal hair shedding or androgenetic alopecia. 9. Subjects in the process of or having completed surgical correction of hair loss in the past 24 months. 10. History of hypersensitivity has been confirmed by application of local anesthetic. 11. A lot of gray hair of the test areas (areas to be injected). 12 Investigator or the sharing researcher has determined to be inappropriate as a target.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phototrichogram of injection site, vital signs, and adverse events until 12 month after injection. | — |
Countries
Japan
Contacts
Public ContactManabu Takahira
SRD Co., Ltd Data Science Department
Outcome results
None listed